Endeavour Vision

What Endeavour Vision does

Endeavour Vision is a Geneva-headquartered venture capital firm that advises the Endeavour Medtech Growth Fund, a €250 million vehicle dedicated to growth-stage medical device and digital health companies in Europe and the United States. Founded in 2000, the firm has executed more than 75 investments across its focus verticals over two decades and operates from offices in Geneva and Boston, with senior investment coverage extending to San Francisco.

The firm invests in companies developing transformative healthcare technologies that address major unmet clinical needs, providing both capital and hands-on support across commercial strategy, clinical trial execution, regulatory submissions, and asset acquisitions. Its team blends entrepreneurs, scientists, and investment professionals (Partners Alexander Schmitz and Damien Tappy, Founder Bernard Vogel, Senior Investment Directors Rob Barmann and Daniel van den Bergh, Investment Director Fernando Pacheco, plus investor relations and strategy functions), and typically takes board seats in portfolio companies such as CeQur, IntelyCare, Kestra, Miach Orthopaedics, Relievant Medsystems, and Virtual Incision.

Endeavour Vision monetizes through standard private-fund economics: management fees on the €250M fund and performance-based carried interest on exits. Its revenue model is therefore recurring management fees supplemented by episodic realized carry from portfolio liquidity events. Notable exits include V-Wave (acquired by Johnson & Johnson for $600M upfront plus milestones), Lumeon (acquired by Health Catalyst in 2024), and Gynesonics (acquired by Hologic). The firm became a UN PRI signatory in May 2019 and maintains an ESG committee for portfolio risk oversight.

Name

Endeavour Vision

Legal name

Endeavour Vision Ltd.

Website

http://www.endeavourvision.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Endeavour Vision is a Geneva-based growth-stage venture capital firm advising the €250M Endeavour Medtech Growth Fund, investing in medical device and digital health companies across Europe and the US with 75+ investments over 20+ years.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare venture capital
• Growth-stage medtech
• Digital health investment
• Medical device financing
• Private equity funds

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Management Fees: Standard private equity/venture capital management fees charged to fund limited partners for asset management services.
2. Carried Interest: Performance-based carried interest from successful portfolio company exits, typically 20% of profits above the hurdle rate.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Endeavour Vision is a growth-stage venture capital firm that invests in medical device and digital health companies across Europe and the United States. The firm manages the €250 million Endeavour Medtech Growth Fund, providing equity capital, board representation, and hands-on strategic support covering commercial strategy, clinical trial execution, regulatory submissions, environmental policy, and asset acquisitions to portfolio companies developing transformative healthcare technologies.

Product overview

Endeavour Vision is an investment firm focused on transformative healthcare technologies. As one of the world's largest and most experienced investment firms focused on medical devices and digital health, the firm does not develop or offer its own products; rather, it supports portfolio companies that develop healthcare technologies. The company's value proposition includes providing capital, strategic guidance, commercial strategy support, clinical trial assistance, environmental policy counsel, regulatory submissions support, and asset acquisition guidance to entrepreneurs developing and commercializing healthcare technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Endeavour Medtech Growth Fund A €250 million closed-end growth-stage venture capital fund dedicated to medical technology and digital health companies in Europe and the U.S., providing equity capital, board representation, and hands-on strategic support across commercial, clinical, regulatory, and corporate development workstreams. The fund is offered to institutional limited partners and deploys capital via direct equity investments, typically leading or co-leading funding rounds from Series B through Series E and beyond.
• Portfolio Strategic Support Services Value-added advisory and operational support services provided to portfolio companies alongside capital, covering commercial strategy development, clinical trial execution, environmental policy guidance, regulatory submission support, and asset acquisition assistance. Services are delivered by Endeavour Vision's investment partners, investment directors, and managers as part of active board representation across holdings such as CeQur, IntelyCare, Kestra, Miach Orthopaedics, and Virtual Incision.

Quantifiable outcome

• 75+ investments executed within focus verticals
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• UN PRI (United Nations Principles for Responsible Investment)coreOthers · 1 May 2019Endeavour Vision became a UN PRI signatory in May 2019, demonstrating commitment to integrating ESG considerations into investment decision-making processes.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Gilde Healthcare: Gilde Healthcare is a specialized Dutch healthcare growth equity and venture capital firm investing across medtech, digital health, and therapeutics in Europe and the US. It is one of the closest direct competitors to Endeavour Vision given its sector focus, stage profile, and transatlantic footprint.
• EQT Life Sciences (formerly LSP): EQT Life Sciences is a European healthcare and life sciences growth investor. LSP was a co-investor with Endeavour in Lumeon's Series D, making it a directly comparable healthcare growth equity peer with overlapping portfolio and similar stage focus.
• MTIP: MTIP is a Swiss-based digital health growth investor. It co-invested alongside Endeavour in Lumeon's Series D, sharing a similar transatlantic digital health investment thesis and growth-stage mandate.
• Forbion: Forbion is a leading European life sciences and healthcare growth investor with significant AUM across multiple funds. It operates a comparable growth-stage healthcare strategy in Europe, making it a direct peer despite some therapeutic-area overlap differences.
• Andera Partners: Andera Partners (formerly Edmond de Rothschild Investment Partners) is a Paris-based growth equity firm with a dedicated Life Sciences practice. It shares Endeavour's European-anchored, growth-stage healthcare investment focus.
• Amadeus Capital Partners: Amadeus Capital Partners is a European technology and healthcare venture investor that co-invested in Lumeon alongside Endeavour Vision. Its deep tech and digital health portfolio makes it a directly comparable growth-stage peer.

Broad incumbents

• Optum Ventures: Optum Ventures is the corporate venture arm of Optum (UnitedHealth Group) and co-led Lumeon's Series D with Endeavour Vision. As a strategic healthcare CVC with a much larger AUM, it represents a broader incumbent with overlapping digital health investment activity.
• Kaiser Permanente Ventures: Kaiser Permanente Ventures is the strategic venture arm of Kaiser Permanente and co-invested with Endeavour in IntelyCare's Series B. As a large healthcare system-affiliated CVC, it is a broader incumbent participating in the same growth-stage healthcare deals.
• New Enterprise Associates (NEA): NEA is a large US venture capital firm that participated in Relievant Medsystems' Series E alongside Endeavour Vision. While not healthcare-dedicated, it is a broad incumbent with meaningful medtech/digital health activity.
• Baird Capital: Baird Capital is the private investment arm of Robert W. Baird and co-led Virtual Incision's Series C with Endeavour Vision. It is a broad growth equity incumbent with a healthcare practice that overlaps with Endeavour's deal activity.

Market position

Strengths4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endeavour-vision

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments69 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endeavour Vision